Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• SEER. Cancer stat facts. 2021 [cited 2022 Sep 14]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United states: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. doi: 10.1371/journal.pone.0139440
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180–1192. doi: 10.1111/j.1742-1241.2011.02799.x
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008 Mar 1;26(7):1148–1159. doi: 10.1200/JCO.2007.12.4487
   PubMed Web of Science ®Google Scholar
• Shore N, Oliver L, Shui I, et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J Urol. 2021 Apr;205(4):977–986.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with Darolutamide. N Engl J Med. 2020 Sep 10;383(11):1040–1049. doi: 10.1056/NEJMoa2001342
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016 Apr 20;34(12):1402–1418. doi: 10.1200/JCO.2015.64.2702
   PubMed Web of Science ®Google Scholar
• Saad F, Bogemann M, Suzuki K, et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):323–334.
   PubMed Web of Science ®Google Scholar
• Erleada® (apalutamide) prescribing information. Horsham (PA): Janssen Products, LP; Sep 2021.
   Google Scholar
• Nubeqa® (darolutamide) prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc; 2022.
   Google Scholar
• Xtandi® (enzalutamide) prescribing information. Northbrook (IL): Astellas Pharma US, Inc; 2022 Jan.
   Google Scholar
• Rice MA, Malhotra SV, Stoyanova T. Second-generation Antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801. doi: 10.3389/fonc.2019.00801
   PubMed Web of Science ®Google Scholar
• Smith MR, Cook R, Lee KA, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011 May 15;117(10):2077–2085. doi: 10.1002/cncr.25762
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Sandin R, Sah J, et al. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US veterans health administration. Cancer Med. 2021 Dec;10(23):8570–8580.
   PubMed Web of Science ®Google Scholar
• Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol. 2017 Oct;72(4):521–531.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2020. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancerfacts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
   Google Scholar
• Dent E, Morley JE, Cruz-Jentoft AJ, et al. Physical frailty: ICFSR international clinical practice guidelines for identification and management. J Nutr Health Aging. 2019;23(9):771–787. doi: 10.1007/s12603-019-1273-z
   PubMed Web of Science ®Google Scholar
• Benoist GE, van Oort IM, Smeenk S, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018 Jan;84(1):122–129.
   PubMed Web of Science ®Google Scholar
• Li H, Hodgson E, Watson L, et al. Comorbidities and concomitant medication use in men with prostate cancer or high levels of PSA compared to matched controls: a GPRD analysis. J Cancer Epidemiol. 2012;2012:1–13. doi: 10.1155/2012/291704
   Google Scholar
• Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):207–219. doi: 10.1038/s41391-019-0195-5
   PubMedGoogle Scholar
• Duran I, Carles J, Bulat I, et al. Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clin Pharmacokinet. 2020 Sep;59(9):1135–1148.
   PubMed Web of Science ®Google Scholar
• Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol. 2012 Sep;23(Suppl 10):x251–x258. doi: 10.1093/annonc/mds325
   PubMed Web of Science ®Google Scholar
• Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011 Nov;7(6):371–374. doi: 10.1200/JOP.2011.000460
   PubMedGoogle Scholar
• Marcath LA, Coe TD, Hoylman EK, et al. Prevalence of drug-drug interactions in oncology patients enrolled on national clinical trials network oncology clinical trials. BMC Cancer. 2018 Nov 22;18(1):1155. doi: 10.1186/s12885-018-5076-0
   PubMedGoogle Scholar
• Keller KL, Franquiz MJ, Duffy AP, et al. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2018 Mar;24(2):110–115.
   PubMed Web of Science ®Google Scholar
• Bossaer JB, Eskens D, Gardner A. Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics. J Oncol Pharm Pract. 2022 Jan;28(1):82–86. doi: 10.1177/1078155220984244
   PubMed Web of Science ®Google Scholar
• Srinivas S, Mohamed AF, Appukkuttan S, et al. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment. Cancer Med. 2020 Sep;9(18):6586–6596.
   PubMed Web of Science ®Google Scholar
• Srinivas S, Appukkuttan S, Mohamed AF, et al. Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). Presented at: 2019 ASCO annual meeting; May 31-June 1, 2019; Chicago, Illinois. J Clin Oncol. 2019;37(15_suppl):e16610. doi: 10.1200/JCO.2019.37.15_suppl.e16610
   Google Scholar
• Shah A, Shah R, Kebede N, et al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J Med Econ. 2020 Apr;23(4):330–346.
   PubMed Web of Science ®Google Scholar
• Zurth C, Koskinen M, Fricke R, et al. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747–759.
   PubMed Web of Science ®Google Scholar
• Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019 Oct;14(5):527–539.
   PubMed Web of Science ®Google Scholar
• Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract. 2014 Jul;10(4):e255–e268.
   PubMedGoogle Scholar
• Optum. Optum claims data. [cited 2022 Aug 11]. Available from: https://www.optum.com/business/life-sciences/real-world-data/claims-data.html
   Google Scholar
• Lexicomp Online. [cited 2022 May 12]. Available from: https://online.lexi.com
   Google Scholar
• Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019 Feb;75(2):285–293.
   PubMed Web of Science ®Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10;17(1):230. doi: 10.1186/s12877-017-0621-2
   PubMedGoogle Scholar
• Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ. 2008 Mar 15;336(7644):606–609. doi: 10.1136/bmj.39503.424653.80
   PubMedGoogle Scholar
• Ingrosso G, Bottero M, Becherini C, et al. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: the radiation oncologist’s perspective. Semin Oncol. 2022 Oct;49(5):409–418.
   PubMed Web of Science ®Google Scholar
• Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017 Apr;55:71–82. doi: 10.1016/j.ctrv.2017.03.001
   PubMed Web of Science ®Google Scholar
• Pollock Y, Smith M, Saad F, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). J Clin Oncol. 2019;37(15_suppl):5025. doi: 10.1200/JCO.2019.37.15_suppl.5025
   Web of Science ®Google Scholar
• Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266–272. doi: 10.18433/J35C7Z
   PubMed Web of Science ®Google Scholar
• Ramos-Esquivel A, Viquez-Jaikel A, Fernandez C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract. 2017 Jul;13(7):e613–e622. doi: 10.1200/JOP.2017.020859
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Jansman FGA, van Leeuwen P, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015 May;26(5):992–997.
   PubMed Web of Science ®Google Scholar
• Diaz-Carrasco MS, Almanchel-Rivadeneyra M, Tomas-Luiz A, et al. Observational study of drug-drug interactions in oncological inpatients. Farm Hosp. 2018 Jan 1;42(1):10–15. doi: 10.7399/fh.10857
   PubMedGoogle Scholar
• Ergun Y, Yildirim Ozdemir N, Toptas S, et al. Drug-drug interactions in patients using tyrosine kinase inhibitors: a multicenter retrospective study. J Buon. 2019 Jul;24(4):1719–1726.
   PubMed Web of Science ®Google Scholar